U.S. Health Policy Reporter, Bloomberg News
I write about U.S. health policy and tweet whatever. Got news? email@example.com or 202.654.4339
politico.com — Don Berwick formally announced Monday that he is running for governor of Massachusetts. Berwick, a Democrat, is a physician and health policy expert who ran Medicare and Medicaid for President Barack Obama. But amid the heated politics of health reform, Republicans refused to confirm him to the position atop CMS. They said his comments praising Britain’s...
bloomberg.com — Provisions in the Affordable Care Act that penalize hospitals for excessive readmissions and encourage employers to offer wellness programs are slowing the growth of U.S. medical costs, even as the economy rebounds. Health-care costs for commercial insurers and employers are expected to rise about 4.5 percent next year after accounting for changes in benefits, PricewaterhouseCoopers LLP said in a report today.
bloomberg.com — A surgeon at Chicago's Sacred Heart Hospital cut a hole in Earl Nattee's throat on Jan. 3, the day before he died. It's not clear why. The medical file contained no explanation of the need for the procedure, called a tracheotomy, according to a state and federal inspection report that quotes Sacred Heart's chief nursing officer as saying it happened "out of the blue."
bloomberg.com — Today's arrest of the mayor of Montreal, Michael Applebaum, on conspiracy and fraud charges, coming on the heels of Toronto's mayor apparently smoking something he shouldn't, is prompting some tut-tutting on the south side of the border. "The mayor of a Canadian city was arrested early this morning and it wasn't even the guy who smoked crack on video," Gawker tweeted.
businessweek.com — Controversy over the name of the National Football League's Washington Redskins surfaced again in May, when 10 members of Congress wrote to the league and Dan Snyder, the team's owner, asking for a change. The legislators said the name is a "racial, derogatory slur" against Native Americans. Snyder
bloomberg.com — Drugmakers can be sued for paying rivals to delay low-cost versions of popular medicines, the U.S. Supreme Court ruled in a decision that shifts the rules governing the release of generic drugs. The 5-3 ruling is largely a victory for the Federal Trade Commission and the Obama administration, reversing a lower court ruling that had effectively insulated pharmaceutical companies from liability.
Sign up to discover more journalists who cover Business and Finance, Health, Politics, Metro D.C. and more.Create An Account
Share This Profile